- Home
- MPU vs MIRA Comparison
MPU vs MIRA Comparison
Compare MPU & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MPU | MIRA |
|---|---|---|
| Founded | 1989 | 2020 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.4M | 43.7M |
| IPO Year | 2023 | 2023 |
Fundamental Metrics
Financial Performance| Metric | MPU | MIRA |
|---|---|---|
| Price | $0.31 | $1.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 73.6K | ★ 119.1K |
| Earning Date | 04-16-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.33 | $0.90 |
| 52 Week High | $4.44 | $2.45 |
Technical Indicators
Market Signals| Indicator | MPU | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | 23.31 | 48.06 |
| Support Level | N/A | $0.99 |
| Resistance Level | $1.00 | $1.22 |
| Average True Range (ATR) | 0.06 | 0.06 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 10.78 | 31.06 |
Price Performance
Historical ComparisonAbout MPU Mega Matrix Corp.
Mega Matrix Corp is a holding company that offers investors an opportunity to participate in the growth of stablecoins, one of the fastest-evolving sectors in digital assets. The company generated revenue from the Membership and top-up streaming services revenue, Online advertising services, and Content licensing. Geographically, the company operates in the United States and Canada, Asia Pacific, Europe middle east and Africa, and Latin America.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.